
Eli Lilly has announced that its trial of abemaciclib, in combination with fulvestrant, had met its primary endpoint of progression-free …

Eli Lilly has announced that, after a pre-planned interim analysis for their Phase III MONARCH2 trial, investigators have decided to …

